The EU Just Gave Monsanto an Early Christmas Present

It renewed approval for the ag giant’s controversial weedkiller, Roundup.

A tractor sprays a field with iherbicides. sauletas/iStock

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

Genetically modified seed and pesticide giant Monsanto has had tough row to hoe lately. The company’s long-proposed marriage with German chemical giant Bayer is undergoing withering scrutiny by regulators in Europe and Brazil, likely putting off its consummation for months. Here in its home country, two states have imposed new rules that could limit the market for Monsanto’s latest blockbuster product, soybeans engineered to resist a controversial herbicide called dicamba. 

But on Monday, Monsanto got good news from across the Atlantic, when the European Union ended a long stalemate and voted to maintain approval for glyphosate, the globe’s most-used herbicide, for another five years. Monsanto owned the original patent on the chemical (which has since expired), and the company maintains a 40 percent share of the global glyphosate market. The European market for glyphosate is worth an annual $1.18 billion, Reuters reports

The voting process was chaotic, The New York Times reports. Germany voted for approval, but only after overcoming a split within its government. France voted nay, and when the result came in, President Emmanuel Macron took to Twitter to vow to ban it in France within three years, spicing his statement with the Trump-trolling hashtag, “#MakeOurPlanetGreatAgain.”

The vote was caught up in the ongoing controversy about whether glyphosate causes cancer. The European Food Safety Agency and the US Environmental Protection Agency (pre-Trump) say, probably not; while the International Agency for Research on Cancer, which evaluates potential carcinogens for the World Health Organization, calls it “probably carcinogenic to humans.” Here’s my look from last year at the subtle difference between how the EFSA and EPA on one side, and the IARC on the other, assessed the herbicide.

Meanwhile, in June, Reuters found that the IARC had finalized its assessment even though the US scientist who led the agency panel on glyphosate, Aaron Blair was aware of then-unpublished data suggesting that glyphosate didn’t seem to cause cancer after all—a controversy Kiera Butler covered at the time. 

Earlier this month, that research was finally published: A large, long-term study of pesticide applicators in North Carolina and Iowa, which found “no association” between glyphosate exposure and most cancers, and “some evidence of increased risk” of acute myeloid leukemia “among the highest exposed group.” The authors added that the potential link requires more study. The IARC, for its part, is standing by its assessment. 


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend